Dudediligence.

Entrada Therapeutics, Inc

TRDANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$19.6MSep ’24$37.4MDec ’24$20.6MMar ’25$1.9MJun ’25$1.6MSep ’25$1.3MDec ’25$875,000Mar ’26$898,000Jun ’26
Net income, by quarter
−$14.0MSep ’24$1.1MDec ’24−$17.3MMar ’25−$43.1MJun ’25−$44.1MSep ’25−$39.2MDec ’25−$39.7MMar ’26−$42.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$129.0M$210.8M$25.4M
Operating income−$51.1M−$97.2M−$3.2M$47.0M−$157.9M
Net income−$51.2M−$94.6M−$6.7M$65.6M−$143.8M
Operating cash flow−$50.9M−$93.8M$139.8M−$41.6M−$128.5M
Free cash flow−$55.4M−$96.7M$134.2M−$44.7M−$129.6M
Cash$291.1M$45.2M$67.6M$101.2M$90.4M
Shares outstanding31.2M31.4M33.4M37.6M38.3M